Tolfenamic acid (DrugBank: Tolfenamic acid)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 5 | 進行性核上性麻痺 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04253132 (ClinicalTrials.gov) | January 1, 2021 | 17/12/2019 | Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks | A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Tolfenamic Acid;Drug: Placebos | NeuroTau, Inc. | The Cleveland Clinic | Not yet recruiting | 40 Years | 85 Years | All | 24 | Phase 1;Phase 2 | United States |